<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11775">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953639</url>
  </required_header>
  <id_info>
    <org_study_id>BP39207</org_study_id>
    <nct_id>NCT02953639</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics</brief_title>
  <official_title>A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter study will assess the effects of 24 weeks of basmisanil treatment on
      cognition and functioning of stable CIAS participants treated with antipsychotics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">August 23, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocomposite Score</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smart phone Based Likert Scale Assessment</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Attend Assessment Questionnaire</measure>
    <time_frame>Baseline, up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nurses' Observation Scale (NOSIE-30)</measure>
    <time_frame>Baseline, up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Extrapyramidal Symptom Rating Scale - Abbreviated Version (ESRS-A)</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline, up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Wechsler Memory Scale Fourth edition, Logical Memory Test (WMS IV-LM) Score</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Ratio Between Trail Making Test (TMT)- Part B and TMT- Part A Scores</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 Schizophrenia Cognition Rating Scale (SCoRS)</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 Clinical Global Impression Severity (CGI-S) Rating</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Improvement (CGI-I) Rating</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Personal and Social Performance (PSP) Total Score</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Schizophrenia Quality of Life Scale (SQLS)</measure>
    <time_frame>Baseline, up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline, up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Basmisanil</measure>
    <time_frame>Pre dose (hour 0) in Days 7, 14, 42, 84, 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution of Basmisanil</measure>
    <time_frame>Pre dose (hour 0) in Days 7, 14, 42, 84, 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Basmisanil</measure>
    <time_frame>Pre dose (hour 0) in Days 7, 14, 42, 84, 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Basmisanil</measure>
    <time_frame>Pre dose (hour 0) in Days 7, 14, 42, 84, 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline, up to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in MCCB Cognitive Domain Scores</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Wechsler Memory Scale Fourth edition, Verbal Paired Associates (WMS IV-PAL) Score</measure>
    <time_frame>Baseline, up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Basmisanil 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive basmisanil twice daily orally for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basmisanil 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive basmisanil twice daily orally for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo to basmisanil twice daily orally for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basmisanil</intervention_name>
    <description>Participants will receive either 80 milligrams (mg) or 240 mg of basmisanil twice daily orally for 24 weeks.</description>
    <arm_group_label>Basmisanil 240 mg</arm_group_label>
    <arm_group_label>Basmisanil 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo-matched to basmisanil orally twice daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia of any type utilizing the Mini International
             Neuropsychiatric Interview (MINI) and diagnostic and statistical manual of mental
             disorders, fifth edition, (DSM-5) direct clinical assessments, family informants and
             past medical records

          -  Evidence of stability of symptoms for 3 months at screening, that is (i.e.), without
             hospitalizations for schizophrenia or increase in level of psychiatric care due to
             worsening of symptoms of schizophrenia

          -  Participants with schizophrenia clinical symptom severity defined by the following:
             hallucinatory behavior item score less than or equal to (&lt;/=) 5 and a delusion item
             score &lt;/= 5 of the PANSS

          -  Participants on a stable regimen of antipsychotic therapy for at least 3 months at
             screening and receiving no more than two antipsychotics

        Exclusion Criteria:

          -  Participants with current DSM-5 diagnosis other than schizophrenia including bipolar
             disorder, schizoaffective disorder and major depressive disorder (MDD)

          -  Clinically significant neurological illness or significant head trauma that affects
             cognitive function, in the judgment of the principal investigator

          -  Full scale intelligence quotient (FSIQ) &lt;70 on the Wechsler Abbreviated Scale of
             Intelligence (WASI-II) at screening

          -  Positive result at screening for hepatitis B (HBV), hepatitis C (HCV), or human
             immunodeficiency virus (HIV)-1 and 2

          -  Moderate to severe substance use disorder (other than nicotine or caffeine), as
             defined by the DSM-5, within the last 12 months

          -  Suicide attempt within one year or currently at risk of suicide in the opinion of the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP39207 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest, LLC</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Booker, J. Gary, MD, APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104-2136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CBH Health</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Louis Clinical Trials</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manhattan Psychiatric Center; Psychopharmacology Research Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
